TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02727881
Drug: Placebo Ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ophthalmic solution
Study: NCT00175903
Drug: Valproate Extended Release
Normalized name: valproate Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Study: NCT03056703
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One Fast Release Tablet containing 1000 mg acetylsalicylic acid
Study: NCT03056703
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
Study: NCT00654628
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
Study: NCT01873989
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02270255
Drug: 1% Xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of 1% Xylocaine
Study: NCT04453384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Study: NCT00622427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets for every night for 2 weeks
Study: NCT01560624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00028886
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00028886
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01386983
Drug: 5ARI
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride or Finasteride
Study: NCT01386983
Drug: 5ARI + AB
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Study: NCT03930992
Drug: standard treatment in HIV positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Study: NCT03930992
Drug: standard treatment in HIV negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Study: NCT03343600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos 2 tablets daily
Study: NCT03437226
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Study: NCT00848744
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT00848744
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT03585140
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg per day orally, before breakfast
Study: NCT00649454
Drug: Metaglip® Tablets 5 mg/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/500mg, single dose fasting
Study: NCT01564706
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT03106532
Drug: PHP-201 0.25% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops daily, 28 days
Study: NCT03106532
Drug: PHP-201 0.5% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops daily, 28 days
Study: NCT03106532
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops daily, 28 days
Study: NCT05651347
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
Study: NCT02388295
Drug: AZD3241
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AZD3241 administered for 12 weeks orally as a tablet.
Study: NCT02388295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
Study: NCT04387097
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: postoperative drip-infusion of remifentanil
Study: NCT03388593
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Study: NCT03388593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Study: NCT01059383
Drug: VECAM 40/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule, orally, once daily at bedtime.
Study: NCT01943552
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT04274803
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
Study: NCT03118830
Drug: Recombinant Follicle Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
Study: NCT04302064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen-matching placebo administered SC
Study: NCT00830193
Drug: D5W Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
Study: NCT03752723
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v.
Study: NCT00117689
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For a minimum of 3 months
Study: NCT02282904
Drug: Cyclophosphamide post transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Study: NCT02282904
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV over one hour Day -6 and -5
Study: NCT00514020
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
Study: NCT00514020
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: through a vein over 2 hours on days 1 and 15.
Study: NCT01092962
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
Study: NCT04560894
Drug: SCT510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
Study: NCT00645463
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CP-945,598 + 240 mg MR Diltiazem
Study: NCT00645463
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CP-945,598 alone
Study: NCT01055678
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
Study: NCT02107872
Drug: REGN1500
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02107872
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02472613
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given for 12 consecutive weeks.
Study: NCT02472613
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
Study: NCT04334564
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos were controls.
Study: NCT01825369
Drug: IV L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT02415790
Drug: E2027 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 matching placebo capsule will be administered.
Study: NCT00756548
Drug: BLI850
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Study: NCT01305512
Drug: SPARC1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
Study: NCT02484027
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
Study: NCT00367211
Drug: PN 200 tablets (500 mg naproxen and 20 mg omeprazole)
Normalized name: esomeprazole 20 MG / naproxen 500 MG [Vimovo]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00367211
Drug: Naproxen 500 mg tablets (PN 200 minus omeprazole)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01495481
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
Study: NCT02194348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02491385
Drug: iv-PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
Study: NCT03594058
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT02645916
Drug: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT00552760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet at bedtime for up to 6 months
Study: NCT01496911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose
Study: NCT03022981
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
Study: NCT03022981
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/VEL FDC 200/50 mg oral granules
Study: NCT05453994
Drug: H. pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIs-based Antimicrobial agents for H. pylori eradication
Study: NCT03327064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
Study: NCT00003558
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03249792
Drug: MK-2118 (IT)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection
Study: NCT03249792
Drug: MK-2118 (SC)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT01782235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01855256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
Study: NCT01860937
Drug: cyclophosphamide based chemotherapy regimens
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00885365
Drug: tobramycin / Bramitob
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
Study: NCT00885365
Drug: tobramycin / TOBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
Study: NCT04328506
Drug: CM082 tablet (test product)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
Study: NCT00253565
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04328506
Drug: CM082 tablet (reference product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
Study: NCT03463772
Drug: In vitro maturation
Normalized name: Vitron-C Reformulated Jul 2016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
Study: NCT00569257
Drug: AEZS-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
Study: NCT04639804
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg tablet
Study: NCT04639804
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg capsule
Study: NCT00492024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 380 mg Microcrystalline Cellulose
Study: NCT03795922
Drug: MT10109L
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109L will be injected into the GL.
Study: NCT03795922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into the GL.
Study: NCT03387631
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01985360
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT03983551
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
Study: NCT00018902
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard anti-depressant treatment with the SSRI fluoxetine
Study: NCT01085123
Drug: Rapimelt
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
Study: NCT01085123
Drug: [11C]AZ10419369
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
Study: NCT01890135
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized double blind
Study: NCT00025623
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01820715
Drug: 600㎍ of DA-3030 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01820715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025623
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01468636
Drug: Oral Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID of oral zinc gluconate x 8 weeks
Study: NCT01468636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID x 8 weeks
Study: NCT01300455
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening
Study: NCT00588913
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03700814
Drug: Co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
Study: NCT01260545
Drug: CA-18C3
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
Study: NCT02538926
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02182635
Drug: Ba253BINEB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538926
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01479621
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
Study: NCT00215826
Drug: Alferon LDO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01721590
Drug: Tongxinluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo,3 capsules/time 3times/day for 1 year
Study: NCT01721590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules/time，3times/day for 1 year
Study: NCT01064687
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01302392
Drug: Best Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).
Study: NCT01064687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00261703
Drug: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
Study: NCT00261703
Drug: Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
Study: NCT01020903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, pre-op
Study: NCT05611086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects in the control group will be given capsules containing placebo (lactose)
Study: NCT01833819
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02450968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02966171
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00569088
Drug: Chinese herbs formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days
Study: NCT01803867
Drug: rHIgM22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IV infusion
Study: NCT02759991
Drug: Hecolin
Normalized name: dehydrocholic acid Oral Tablet [Decholin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
Study: NCT02759991
Drug: Hepa-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
Study: NCT01329744
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection given twice per day of placebo compound, for 24 weeks